Biotechnology company Celularity Inc. (NASDAQ: CELU) has recently reached a strategic licensing agreement totaling 35 million dollars.

This transaction has significantly strengthened the company's capital position, providing robust financial support for its core strategy focused on extending human healthspan. This collaboration not only brings substantial non-dilutive funding to Celularity, but will also accelerate the development of innovative therapies based on placental-derived stem cell technology, marking a key step forward in the company's pursuit of its "longevity strategy."